Erika Van Landuyt
Overview
Explore the profile of Erika Van Landuyt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thys K, Loza M, Lynn L, Callewaert K, Varma L, Crabbe M, et al.
Sci Rep
. 2024 Oct;
14(1):22981.
PMID: 39362933
We examined candidate biomarkers for efficacy outcomes in hospitalized COVID-19 patients who were treated with sirukumab, an IL-6 neutralizing antibody, in a randomized, double-blind, placebo-controlled, phase 2 trial. Between May...
2.
Gottlieb R, Clement M, Cook P, Deveikis A, Foong K, Robinson P, et al.
J Infect
. 2024 Aug;
89(4):106241.
PMID: 39182655
Background: Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials. Methods:...
3.
Van Hemelryck S, Van Landuyt E, Hufkens V, Vanveggel S
Antivir Ther
. 2024 May;
29(2):13596535241248282.
PMID: 38725258
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) was developed as a once-daily, complete antiretroviral (ARV) regimen therapy to address the need for simplified protease inhibitor-based ARV regimens. This study assessed...
4.
Van Hemelryck S, Van Landuyt E, Ariyawansa J, Vanveggel S, Palmer M
Clin Pharmacol Drug Dev
. 2023 Jun;
12(11):1060-1068.
PMID: 37335552
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a fixed-dose combination (FDC) for the treatment of HIV-1 infection in adults and adolescents weighing 40 kg or greater. This Phase 1, randomized, open-label,...
5.
DAmico R, Cenoz Gomis S, Moodley R, Van Solingen-Ristea R, Baugh B, Van Landuyt E, et al.
HIV Med
. 2022 Aug;
24(2):202-211.
PMID: 35945163
Objectives: Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen....
6.
Huhn G, Wilkin A, Mussini C, Spinner C, Jezorwski J, El Ghazi M, et al.
HIV Res Clin Pract
. 2021 Feb;
21(6):151-167.
PMID: 33528318
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective: To describe a Week 96 pre-planned subgroup analysis of D/C/F/TAF...
7.
Lathouwers E, Weinsteiger S, Baugh B, Ghys A, Jezorwski J, Mohsine E, et al.
J Med Virol
. 2020 Dec;
93(6):3985-3990.
PMID: 33300183
In AMBER and EMERALD, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg demonstrated high virological response and low virological failure (VF) through week 96. Week 96 resistance analyses are presented. Post-baseline samples for...
8.
Orkin C, Eron J, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, et al.
AIDS
. 2019 Dec;
34(5):707-718.
PMID: 31833849
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in AMBER (NCT02431247). Methods: Treatment-naive, HIV-1-positive adults [screening plasma viral load ≥1000 copies/ml; CD4 cell count >50 cells/μl) were...
9.
Lathouwers E, Wong E, Brown K, Baugh B, Ghys A, Jezorwski J, et al.
AIDS Res Hum Retroviruses
. 2019 Sep;
36(1):48-57.
PMID: 31516033
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance...
10.
Huhn G, Eron J, Girard P, Orkin C, Molina J, DeJesus E, et al.
AIDS Res Ther
. 2019 Aug;
16(1):23.
PMID: 31464642
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing boosted protease inhibitor (bPI) + emtricitabine/tenofovir...